About
Antigen Design Technology for New Functional Blocking Antibodies
Tikcro Technologies is leveraging a novel 3D antigen design technology in order to generate new antibodies that block receptor/ligand surface domains of immune modulators and re-activate the body's immune system to fight cancer. The company has had extensive collaborative research with the Weizmann Institute of Science in Israel.
Identity
| Name | Tikcro Technologies |
|---|---|
| Slug | tikcro-technologies |
| Former names | Tioga |
| Type / kind | startup |
| Crunchbase ID | tikcro |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Pvo5McIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, May 2021 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Ness Ziona, Israel |
Web & social
| Website | https://tikcro.com/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business models
B2B
Tags
cancerpharmaceuticalsdrug-developmentbiotechnologybiopharmaceutical
Funding
| Total raised | — |
|---|---|
| Current stage | Mature |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}